IDEAS home Printed from https://ideas.repec.org/p/hal/journl/halshs-02900915.html
   My bibliography  Save this paper

The influence of local institutional and historical frameworks on a globalized industry: The case of the pharmaceutical industry in France and Quebec

Author

Listed:
  • Maé Geymond

    (CES - Centre d'économie de la Sorbonne - UP1 - Université Paris 1 Panthéon-Sorbonne - CNRS - Centre National de la Recherche Scientifique, UP1 - Université Paris 1 Panthéon-Sorbonne)

Abstract

In this paper, we combine the Varieties of Capitalism and the global value chain approaches, considering the interaction between lead firms' global strategies and national capitalism, to show how local pharmaceutical employment results from this interaction. Our analysis is grounded in the comparison between France and Quebec. The first part presents the relevant differences in both historical and institutional elements. Second, after highlighting the similarities that can be attributed to global dynamics, we detail the mechanisms by which local institutions shape the global value chain implantation, giving different forms to the employment structure and dynamics. We show that France is clearly oriented towards manufacturing activity because of industrial history and market features, whereas Quebec has a commercial specialty and an outsourced R&D as a result of high prices and the global organization of research.

Suggested Citation

  • Maé Geymond, 2020. "The influence of local institutional and historical frameworks on a globalized industry: The case of the pharmaceutical industry in France and Quebec," Post-Print halshs-02900915, HAL.
    • Handle: RePEc:hal:journl:halshs-02900915
    Note: View the original document on HAL open archive server: https://shs.hal.science/halshs-02900915
    as

    Download full text from publisher

    File URL: https://shs.hal.science/halshs-02900915/document
    Download Restriction: no
    ---><---

    References listed on IDEAS

    as
    1. Cristina Fróes de Borja Reis & André Barroso de Souza, 2018. "Drawing value curves: lessons from financial statements of the world’s biggest manufacturing corporations," Revue d'économie industrielle, De Boeck Université, vol. 0(3), pages 229-262.
    2. Coralie Perez & Nadine Thèvenot & Nathalie Berta & Delphine Brochard & Noélie Delahaie & Sophie Jallais & Corinne Perraudin & Catherine Sauviat & Julie Valentin, 2015. "Modes d’ajustement par le travail en temps de crise : des relations professionnelles sous tension," Post-Print hal-01306493, HAL.
    3. Geoffroy Labrouche & Med Kechidi, 2016. "La stratégie d'innovation ouverte de Sanofi," Post-Print hal-01346730, HAL.
    4. Matthieu Montalban, 2011. "La financiarisation des Big Pharma : de l'insoutenable modèle blockbuster à son dépassement ?," Post-Print hal-00651718, HAL.
    5. Coralie Perez & Nadine Thèvenot & Nathalie Berta & Delphine Brochard & Noélie Delahaie & Sophie Jallais & Corinne Perraudin & Catherine Sauviat & Julie Valentin, 2015. "Modes d’ajustement par le travail en temps de crise : des relations professionnelles sous tension," Université Paris1 Panthéon-Sorbonne (Post-Print and Working Papers) hal-01306493, HAL.
    6. Vincent Frigant & Cédric Durand & David Flacher, 2018. "Etudier les chaines globales de valeur comme une forme d’organisation industrielle," Post-Print hal-02150265, HAL.
    7. Dominique Foray & Stéphane Lhuillery, 2010. "Structural changes in industrial R&D in Europe and the US: towards a new model?," Science and Public Policy, Oxford University Press, vol. 37(6), pages 401-412, July.
    8. Patricia M. Danzon & Andrew Epstein & Sean Nicholson, 2007. "Mergers and acquisitions in the pharmaceutical and biotech industries," Managerial and Decision Economics, John Wiley & Sons, Ltd., vol. 28(4-5), pages 307-328.
    9. Patrick Pauriche & Frédéric Rupprecht, 1998. "Le secteur pharmaceutique, un secteur aux multiples enjeux," Économie et Statistique, Programme National Persée, vol. 312(1), pages 7-20.
    10. Philippe Abecassis & Nathalie Coutinet, 2017. "Les politiques du médicament dans un contexte d’austérité en France et au Royaume-Uni : quel impact sur le modèle de production des big pharma ?," CEPN Working Papers 2017-01, Centre d'Economie de l'Université de Paris Nord.
    11. Cédric Durand & David Flacher & Vincent Frigant, 2018. "Étudier les chaînes globales de valeur comme une forme d’organisation industrielle," Revue d'économie industrielle, De Boeck Université, vol. 0(3), pages 13-34.
    12. Bruno Amable, 2005. "Les cinq capitalismes. Diversité des systèmes économiques et sociaux dans la mondialisation," Université Paris1 Panthéon-Sorbonne (Post-Print and Working Papers) halshs-00310487, HAL.
    13. Enda Hannon, 2016. "Industrial policy and employment in the UK: evidence from the pharmaceutical sector," Industrial Relations Journal, Wiley Blackwell, vol. 47(1), pages 2-20, January.
    14. Lexchin, Joel, 1997. "After compulsory licensing: coming issues in Canadian pharmaceutical policy and politics," Health Policy, Elsevier, vol. 40(1), pages 69-80, April.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Ines Kersan-Škabić & Alen Belullo, 2021. "The Characteristics of Regional Value Chains in the Sector of Chemicals and Pharmaceutical Products in the EU," Economies, MDPI, vol. 9(4), pages 1-24, November.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Maé Geymond, 2020. "The influence of local institutional and historical frameworks on a globalized industry: The case of the pharmaceutical industry in France and Quebec," Université Paris1 Panthéon-Sorbonne (Post-Print and Working Papers) halshs-02900915, HAL.
    2. Maé Geymond, 2020. "The influence of local institutional and historical frameworks on a globalized industry: The case of the pharmaceutical industry in France and Quebec," Documents de travail du Centre d'Economie de la Sorbonne 20011, Université Panthéon-Sorbonne (Paris 1), Centre d'Economie de la Sorbonne.
    3. Maé Geymond & Coralie Perez & Corinne Perraudin & Nadine Thevenot & Julie Valentin & Francois-Xavier Devetter, 2019. "Entreprise éclatée et périmètre de la représentation collective," Post-Print hal-03895478, HAL.
    4. Thomas Amossé & Philippe Askenazy & Martin Chevalier & Christine Erhel & Héloïse Petit & Antoine Rebérioux, 2016. "Industrial Relations and Firms’ Reactions to the Recession: A Comparative Micro-Econometric Analysis of France and Great Britain [Relations sociales et ajustements à la crise : une analyse micro-st," Université Paris1 Panthéon-Sorbonne (Post-Print and Working Papers) hal-02172455, HAL.
    5. Delphine Brochard & Corinne Perraudin, 2017. "Crisis adjustment strategies in France: The contribution of establishment-level data," Université Paris1 Panthéon-Sorbonne (Post-Print and Working Papers) hal-03227744, HAL.
    6. Christos Genakos & Andreas Lamprinidis & James Walker, 2023. "Evaluating merger effects," CEP Discussion Papers dp1921, Centre for Economic Performance, LSE.
    7. Pietro Moncada-Paternò-Castello, 2022. "Top R&D investors, structural change and the R&D growth performance of young and old firms," Eurasian Business Review, Springer;Eurasia Business and Economics Society, vol. 12(1), pages 1-33, March.
    8. Abhirup Chakrabarti, 2015. "Organizational adaptation in an economic shock: The role of growth reconfiguration," Strategic Management Journal, Wiley Blackwell, vol. 36(11), pages 1717-1738, November.
    9. Ye Jin Lee & Kwangsoo Shin & Eungdo Kim, 2019. "The Influence of a Firm’s Capability and Dyadic Relationship of the Knowledge Base on Ambidextrous Innovation in Biopharmaceutical M&As," Sustainability, MDPI, vol. 11(18), pages 1-17, September.
    10. Valérie Revest & Alessandro Sapio, 2016. "Graduation and sell-out strategies in the Alternative Investment Market," Discussion Papers 4_2016, CRISEI, University of Naples "Parthenope", Italy.
    11. Billette de Villemeur, Etienne & Versaevel, Bruno, 2019. "One lab, two firms, many possibilities: On R&D outsourcing in the biopharmaceutical industry," Journal of Health Economics, Elsevier, vol. 65(C), pages 260-283.
    12. Luca Verginer & Federica Parisi & Jeroen van Lidth de Jeude & Massimo Riccaboni, 2022. "The Impact of Acquisitions in the Biotechnology Sector on R&D Productivity," Papers 2203.12968, arXiv.org, revised Jan 2024.
    13. Elisa Barbieri & Manli Huang & Shenglei Pi & Mattia Tassinari, 2017. "Restructuring the Production of Medicines: An Investigation on the Pharmaceutical Sector in China and the Role of Mergers and Acquisitions," IJERPH, MDPI, vol. 14(10), pages 1-21, October.
    14. Christine Erhel & Mathilde Guergoat-Larivière, 2010. "Labour Market Status, Transitions and Gender: a European Perspective," Post-Print hal-00616799, HAL.
    15. Pietro Moncada-Paternò-Castello & Sara Amoroso & Michele Cincera, 0. "Corporate R&D intensity decomposition: different data, different results?," Science and Public Policy, Oxford University Press, vol. 47(4), pages 458-473.
    16. Jinhee Kwon & Cheong Kim & Kun Chang Lee, 2020. "Moderating Effect of the Continental Factor on the Business Strategy and M&A Performance in the Pharmaceutical Industry for Sustainable International Business," Sustainability, MDPI, vol. 12(12), pages 1-14, June.
    17. Malek, Jan & Newham, Melissa & Seldeslachts, Jo & Veugelers, Reinhilde, 2024. "Acquiring R&D projects: who, when, and what? Evidence from antidiabetic drug development," CEPR Discussion Papers 18816, C.E.P.R. Discussion Papers.
    18. Anna Rita Bennato & Stephen Davies & Franco Mariuzzo & Peter Ormosi, 2019. "Mergers and Innovation: Evidence from the Hard Disk Drive Market," Working Paper series, University of East Anglia, Centre for Competition Policy (CCP) 2018-04v3, Centre for Competition Policy, University of East Anglia, Norwich, UK..
    19. Ralph Siebert & Zhili Tian, 2020. "Dynamic Mergers Effects on R&D Investments and Drug Development across Research Phases in the Pharmaceutical Industry," CESifo Working Paper Series 8303, CESifo.
    20. Dutraive, Véronique, 2009. "Economic Development and Institutions," Revue de la Régulation - Capitalisme, institutions, pouvoirs, Association Recherche et Régulation, vol. 6.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:hal:journl:halshs-02900915. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: CCSD (email available below). General contact details of provider: https://hal.archives-ouvertes.fr/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.